Robert S. Ohgami, MD, PhD, FCAP

Professor, University of Utah School of Medicine

Specialties

• Hematopathology
• Molecular pathology
• Translational research
• Innovation

Education

• Medical Degree—Harvard Medical School
• Doctorate Degree—Harvard University
• Residency—Anatomic Pathology, Stanford University
• Fellowship—Hematopathology, Stanford University

Certification/Affiliations

• American Board of Pathology: Anatomic Pathology and Hematology
• University of Utah David Eccles School of Business: Leading with Equity, Diversity, and Inclusion

Research Interests

• Translational molecular pathology
• Clinical laboratory testing
• Hematopathology
• Applied artificial intelligence

Awards

• Berard-Dorfman Founders Award, Society for Hematopathology
• Faculty Scholar Mentor, Fulbright U.S. Scholar Program
• Principal Investigator and Mentor, Regeneron Science Talent Search Scholar
• Anatomic Pathology Junior Faculty Teaching Award, Stanford University Department of Pathology
• Clinical Pathology Junior Faculty Teaching Award, Stanford University Department of Pathology
• Cum Laude, Harvard Medical School
• Summa Cum Laude, Princeton University
• Pyka Prize for Excellence in Physics, Princeton University

Recent Publications

• Guney E, Lucas CG, Singh K, et al. Molecular profiling identifies at least 3 distinct types of posttransplant lymphoproliferative disorder involving the CNS. Blood Adv. 2023;7(13):3307-3311.
• Ohgami RS, Aung PP, Gru AA, et al. An analysis of the pathologic features of blastic plasmacytoid dendritic cell neoplasm based on a comprehensive literature database of cases. Arch Pathol Lab Med. 2023;147(7):837-846.
• Xiao A, Shahmarvand N, Nagy A, et al. TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature. Front Oncol. 2023;13:1174606.
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms [published correction appears in Leukemia. 2023;37(9):1944-1951]. Leukemia. 2022;36(7):1720-1748.
• Butzmann A, Sridhar K, Jangam D, et al. Mutations in JAK/STAT and NOTCH1 genes are enriched in post-transplant lymphoproliferative disorders. Front Oncol. 2022;11:790481.
• Güney E, Lucas CG, Qi Z, et al. A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. Blood Adv. 2022;6(10):3189-3193.
• Kikuchi A, Singh K, Gars E, et al. Pathology updates and diagnostic approaches to haemophagocytic lymphohistiocytosis. Histopathology. 2022;80(4):616-626.
• Lu KL, Menke JR, Ng D, et al. Cytomorphologic features of pediatric-type follicular lymphoma on fine needle aspiration biopsy: case series and a review of the literature. J Am Soc Cytopathol. 2022;11(5):281-294.
• Saglam A, Singh K, Gollapudi S, et al. Indolent T-lymphoblastic proliferation: a systematic review of the literature analyzing the epidemiologic, clinical, and pathologic features of 45 cases. Int J Lab Hematol. 2022;44(4):700-711.
• Singh KI, Gollapudi S, Kumar J, et al. Case report: Castleman disease with an associated stromal spindle cell proliferation, PDGFRB mutation and p53 expression: clonal origins of a rare disease. Front Oncol. 2022;12:857606.
• Butzmann A, Kumar J, Sridhar K, et al. A review of genetic abnormalities in unicentric and multicentric Castleman disease. Biology (Basel). 2021;10(4):251.
• Chen JA, Hou Y, Roskin KM, et al. Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. Blood Adv. 2021;5(17):3492-3496.
• Han SY, Mrózek K, Voutsinas J, et al. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv. 2021;5(10):2481-2489.
• Kennedy VE, Ruiz-Cordero R, Jangam D, et al. A case of EBV-negative aggressive NK-cell leukemia: use of next-generation sequencing in demystifying a diagnostic dilemma and guiding clinical care. Clin Lymphoma Myeloma Leuk. 2021;21(7):e583-e587.
• Ling H, Sridhar K, Gollapudi S, et al. Measurement of cell volume using in-line digital holography. Microscopy (Oxf). 2021;70(4):333-339.
• Singh K, Mittal S, Gollapudi S, et al. A meta-analysis of SARS-CoV-2 patients identifies the combinatorial significance of D-dimer, C-reactive protein, lymphocyte, and neutrophil values as a predictor of disease severity. Int J Lab Hematol. 2021;43(2):324-328.
• Singh K, Gollapudi S, Mittal S, et al. Point mutation specific antibodies in B-cell and T-cell lymphomas and leukemias: targeting IDH2, KRAS, BRAF and other biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2. Diagnostics (Basel). 2021;11(4):600.
• Ustun C, Morgan EA, Ritz EM, et al. Core-binding factor acute myeloid leukemia with inv(16): older age and high white blood cell count are risk factors for treatment failure. Int J Lab Hematol. 2021;43(1):e19-e25.
• Yang F, Nielsen SCA, Hoh RA, et al. Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues. Science. 2021;372(6543):738-741.
• Brar N, Butzmann A, Kumar J, et al. LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia/lymphoma from indolent T-lymphoblastic proliferations. Histopathology. 2020;77(6):984-988.
• Butzmann A, Sridhar K, Jangam D, et al. A comprehensive analysis of RHOA mutation positive and negative angioimmunoblastic T-cell lymphomas by targeted deep sequencing, expression profiling and single cell digital image analysis. Int J Mol Med. 2020;46(4):1466-1476.
• Gars E, Butzmann A, Ohgami R, et al. The life and death of the germinal center. Ann Diagn Pathol. 2020;44:151421.
• Hoffmann JC, Atwater SK, Hong E, et al. A long-term study of persistent Sézary syndrome: evidence for antigen shift by multiparameter flow cytometry and its significance in overall survival. Am J Dermatopathol. 2020;42(6):389-396.
• Jangam D, Sridhar K, Butzmann A, et al. TBL1XR1 mutations in primary marginal zone lymphomas of ocular adnexa are associated with unique morphometric phenotypes. Curr Eye Res. 2020;45(12):1583-1589.
• Lauw MIS, Lucas CG, Ohgami RS, et al. Primary central nervous system lymphomas: a diagnostic overview of key histomorphologic, immunophenotypic, and genetic features. Diagnostics (Basel). 2020;10(12):1076.
• Tsai AG, Glass DR, Juntilla M, et al. Multiplexed single-cell morphometry for hematopathology diagnostics. Nat Med. 2020;26(3):408-417.
• Wang L, Ashraf DC, Kinde B, et al. Hypodiploid B-lymphoblastic leukemia presenting as an isolated orbital mass prior to systemic involvement: a case report and review of the literature. Diagnostics (Basel). 2020;11(1):25.
• Wen KW, Fakhri B, Menke J, et al. Complexities in the diagnosis of large B-cell lymphomas, classic Hodgkin lymphomas and overlapping peripheral T-cell lymphomas simplified: an evidence-based guide. Ann Diagn Pathol. 2020;46:151534.
• Werstein B, Dunlap J, Cascio MJ, et al. Molecular discordance between myeloid sarcomas and concurrent bone marrows occurs in actionable genes and is associated with worse overall survival. J Mol Diagn. 2020;22(3):338-345.
• Yao K, Singh A, Sridhar K, et al. Artificial intelligence in pathology: a simple and practical guide. Adv Anat Pathol. 2020;27(6):385-393.
• Hoffmann JC, Lin CY, Bhattacharyya S, et al. Rosai-Dorfman disease of the breast with variable IgG4+ plasma cells: A diagnostic mimicker of other malignant and reactive entities. Am J Surg Pathol. 2019;43(12):1653-1660.
• Kumar J, Butzmann A, Wu S, et al. Indolent in situ B-cell neoplasms with MYC rearrangements show somatic mutations in MYC and TNFRSF14 by next-generation sequencing. Am J Surg Pathol. 2019;43(12):1720-1725.
• Sridhar K, Singh A, Butzmann A, et al. Molecular genetic testing methodologies in hematopoietic diseases: current and future methods. Int J Lab Hematol. 2019;41 Suppl 1:102-116.